Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...
Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback